HRTX Shares Outstanding History



Below is a table of the HRTX shares outstanding history going back to 1/13/2014:

Date HRTX Shares Outstanding
1/13/20140.02B
1/23/201415.68M
2/28/201423.72M
4/28/201423.90M
7/29/201428.91M
10/29/201429.18M
3/2/201529.53M
4/28/201529.63M
7/23/201535.69M
10/26/201535.97M
2/4/201636.23M
4/26/201636.66M
7/29/201639.05M
10/27/201639.19M
2/3/201753.57M
4/17/201753.70M
7/26/201754.14M
10/25/201754.50M
2/1/201864.65M
4/25/201871.95M
7/24/201877.73M
10/26/201878.02M
2/1/201978.18M
4/18/201979.07M
7/17/201979.82M
10/30/201990.05M
2/3/202090.37M
4/29/202090.64M
7/29/202090.86M
10/29/202090.86M
2/5/202191.40M
5/4/2021101.83M
7/29/2021101.91M
10/28/2021101.94M
2/4/2022102.14M
5/3/2022102.48M
8/1/2022102.63M
11/1/2022118.89M
3/14/2023119.26M
5/1/2023119.71M
7/25/2023140.76M
11/8/2023150.07M
2/28/2024150.33M

Also see: HRTX Market Cap History
HRTX YTD Return
HRTX Historical Shares Outstanding:
+25.00% CAGR
HRTX Historical Shares Outstanding: +25.00% CAGR

Mouse over chart for data details
1/13/2014 ...2/28/2024
Heron Therapeutics is a commercial-stage biotechnology company focused on developing treatments for acute care and oncology patients. Co.'s oncology care product portfolio includes SUSTOL, which is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide combination chemotherapy regimens. Co.'s acute care product portfolio includes: ZYNRELEF, which is indicated in adults for soft tissue or periarticular instillation; and APONVIE (HTX-019), which is indicated for the prevention of postoperative nausea and vomiting in adults. We show 43 historical shares outstanding datapoints in our coverage of HRTX's shares outstanding history.

Understanding the changing numbers of HRTX shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like HRTX versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching HRTX by allowing them to research HRTX shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree HRTX Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Heron Therapeutics (HRTX) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

HSCS Shares Outstanding History
HSDT Shares Outstanding History
HSGX Shares Outstanding History
HSIC Shares Outstanding History
HSKA Shares Outstanding History
HSTO Shares Outstanding History
HTBX Shares Outstanding History
HTGM Shares Outstanding History
HUMA Shares Outstanding History
HYH Shares Outstanding History
More Healthcare companies »

 

HRTX Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2024, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 9.5%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 9.5%.